PL3383392T3 - Schematy dawkowania dla 2-hydroksy-6-((2-(1-izopropylo-1H-pirazol-5-ilo)pirydyn3-ylo)metoksy)benzaldehydu - Google Patents

Schematy dawkowania dla 2-hydroksy-6-((2-(1-izopropylo-1H-pirazol-5-ilo)pirydyn3-ylo)metoksy)benzaldehydu

Info

Publication number
PL3383392T3
PL3383392T3 PL16813299.1T PL16813299T PL3383392T3 PL 3383392 T3 PL3383392 T3 PL 3383392T3 PL 16813299 T PL16813299 T PL 16813299T PL 3383392 T3 PL3383392 T3 PL 3383392T3
Authority
PL
Poland
Prior art keywords
pyrazol
benzaldehyde
pyridin
methoxy
isopropyl
Prior art date
Application number
PL16813299.1T
Other languages
English (en)
Inventor
Eleanor L. Ramos
Joshua Eli LEHRER-GRAIWER
Athiwat Hutchaleelaha
Naveen BEJUGAM
Original Assignee
Global Blood Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57570625&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3383392(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Global Blood Therapeutics, Inc. filed Critical Global Blood Therapeutics, Inc.
Publication of PL3383392T3 publication Critical patent/PL3383392T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
PL16813299.1T 2015-12-04 2016-12-02 Schematy dawkowania dla 2-hydroksy-6-((2-(1-izopropylo-1H-pirazol-5-ilo)pirydyn3-ylo)metoksy)benzaldehydu PL3383392T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562263554P 2015-12-04 2015-12-04
US201662375832P 2016-08-16 2016-08-16
PCT/US2016/064723 WO2017096230A1 (en) 2015-12-04 2016-12-02 Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Publications (1)

Publication Number Publication Date
PL3383392T3 true PL3383392T3 (pl) 2025-11-17

Family

ID=57570625

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16813299.1T PL3383392T3 (pl) 2015-12-04 2016-12-02 Schematy dawkowania dla 2-hydroksy-6-((2-(1-izopropylo-1H-pirazol-5-ilo)pirydyn3-ylo)metoksy)benzaldehydu

Country Status (16)

Country Link
US (4) US11020382B2 (pl)
EP (1) EP3383392B1 (pl)
BR (1) BR112018011272A2 (pl)
DK (1) DK3383392T3 (pl)
ES (1) ES3039236T3 (pl)
FI (1) FI3383392T3 (pl)
HU (1) HUE072191T2 (pl)
IL (1) IL259798A (pl)
MA (1) MA43373A (pl)
MX (2) MX384797B (pl)
PL (1) PL3383392T3 (pl)
PT (1) PT3383392T (pl)
SG (2) SG11201804647TA (pl)
SI (1) SI3383392T1 (pl)
TW (1) TW201731509A (pl)
WO (1) WO2017096230A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2797597B1 (en) 2011-12-28 2020-02-26 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
PT3141542T (pt) 2011-12-28 2020-06-16 Global Blood Therapeutics Inc Compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos
AU2014237330A1 (en) 2013-03-15 2015-09-17 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
ES2890077T3 (es) 2013-03-15 2022-01-17 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de la hemoglobina
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AU2014237340C1 (en) 2013-03-15 2018-11-08 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
PL3102208T5 (pl) 2014-02-07 2024-10-14 Global Blood Therapeutics, Inc. Krystaliczny polimorf wolnej zasady 2-hydroksy-6-((2-(1-izopropylo-1h-pirazol-5-ilo)pirydyn-3-ylo)metoksy)benzaldehydu
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
PL3383392T3 (pl) 2015-12-04 2025-11-17 Global Blood Therapeutics, Inc. Schematy dawkowania dla 2-hydroksy-6-((2-(1-izopropylo-1H-pirazol-5-ilo)pirydyn3-ylo)metoksy)benzaldehydu
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TW202332423A (zh) * 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
ES2966707T3 (es) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Moduladores de la hemoglobina para el tratamiento de la drepanocitosis
WO2020106642A1 (en) 2018-11-19 2020-05-28 Global Blood Therapeutics, Inc. 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin
CR20210284A (es) 2018-11-29 2021-07-09 Pfizer Pirazoles como modulares de hemoglobina
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
WO2021101910A1 (en) 2019-11-19 2021-05-27 Global Blood Therapeutics, Inc. Methods of administering voxelotor
CN112047924B (zh) * 2020-10-10 2023-04-18 山东汇海医药化工有限公司 一种沃克洛多的制备方法
AU2022381755A1 (en) 2021-11-05 2024-05-16 Global Blood Therapeutics, Inc. Methods of treating sickle cell disease with voxelotor

Family Cites Families (265)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE276479C (pl)
DE226590C (pl)
DE258226C (pl)
BE558821A (pl) 1956-02-13 1900-01-01
BE787580A (fr) 1971-08-13 1973-02-14 Hoechst Ag Procede de preparation de derives du furanne
BE787576A (fr) 1971-08-13 1973-02-14 Hoechst Ag Derives de benzofuranne et leur utilisation comme azureurs optiques
GB1409865A (en) 1973-02-13 1975-10-15 Science Union & Cie Dihydropyridines derivatives their preparation and pharmaceu tical compositions containing them
GB1593417A (en) 1976-12-22 1981-07-15 Squibb & Sons Inc Carbocyclic-fused pyrazolopyridine derivatives
US4062858A (en) 1976-12-22 1977-12-13 E. R. Squibb & Sons, Inc. Derivatives of 5,6-dihydrobenzo[5,6]cyclohepta[1,2-b]pyrazolo[4,3-e]pyridin-11(1H)-ones and 11(1H)-imines
EP0010063B1 (de) 1978-10-04 1982-12-29 Ciba-Geigy Ag Verfahren zur Herstellung von Furanyl-benzazolen
DE2853765A1 (de) 1978-12-13 1980-06-26 Bayer Ag Verfahren zur herstellung von benzimidazolylbenzofuranen
DE2904829A1 (de) 1979-02-08 1980-08-14 Bayer Ag Verfahren zur herstellung von benzimidazolylbenzofuran
JPS5649335A (en) 1979-06-29 1981-05-02 Wellcome Found Ether compound
GR76950B (pl) 1980-12-18 1984-09-04 Wellcome Found
JPS5929667A (ja) 1982-08-13 1984-02-16 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体および強心剤
US4478834A (en) 1983-02-11 1984-10-23 Usv Pharmaceutical Corporation Dihydropyridines and their use in the treatment of asthma
GB8402740D0 (en) 1984-02-02 1984-03-07 Scras Furo-(3 4-c)-pyridine derivatives
JPS6140236A (ja) 1984-08-02 1986-02-26 Yamanouchi Pharmaceut Co Ltd ハイドロキノン誘導体
DE3431004A1 (de) 1984-08-23 1986-03-06 Hoechst Ag, 6230 Frankfurt Neue 3-pyridylverbindungen und verfahren zu ihrer herstellung
GB8603475D0 (en) 1986-02-12 1986-03-19 Glaxo Group Ltd Chemical compounds
DK111387A (da) 1986-03-05 1987-09-06 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf, laegemiddel indeholdende saadanne derivater samt fremgangsmaade til fremstilling af derivaterne
US4831041A (en) 1986-11-26 1989-05-16 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine compounds and processes for preparation thereof
AU598093B2 (en) 1987-02-07 1990-06-14 Wellcome Foundation Limited, The Pyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof
JPH07121937B2 (ja) 1987-03-18 1995-12-25 大塚製薬株式会社 カルボスチリル誘導体
JPS63258463A (ja) 1987-04-14 1988-10-25 Kumiai Chem Ind Co Ltd 2−フエノキシピリミジン誘導体及び除草剤
GB8711802D0 (en) 1987-05-19 1987-06-24 Fujisawa Pharmaceutical Co Dithioacetal compounds
GB8718940D0 (en) 1987-08-11 1987-09-16 Glaxo Group Ltd Chemical compounds
US4920131A (en) 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
JP2650038B2 (ja) 1988-01-27 1997-09-03 サントリー株式会社 ピロリチジン化合物およびその用途
JPH01305081A (ja) 1988-04-04 1989-12-08 E R Squibb & Sons Inc 3―アシルアミノ―1―[[[(置換スルホニル)アミノ〕カルボニル〕アミノ〕―2―アゼチジノン類
US4952574A (en) 1988-09-26 1990-08-28 Riker Laboratories, Inc. Antiarrhythmic substituted N-(2-piperidylmethyl)benzamides
IE81170B1 (en) 1988-10-21 2000-05-31 Zeneca Ltd Pyridine derivatives
DD276480A1 (de) 1988-10-26 1990-02-28 Fahlberg List Veb Verfahren zur herstellung von naphtho/2,1-b/fur-2-ylchinoxalinen
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
IT1230859B (it) 1989-06-05 1991-11-08 Corvi Camillo Spa 2 alchinilfenoli sostituiti ad azione anti infiammatoria, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
GB2244054B (en) 1990-04-19 1994-04-06 Ici Plc Pyridine derivatives
IL98526A0 (en) 1990-06-18 1992-07-15 Merck & Co Inc Pyridones,processes for their preparation and pharmaceutical compositions containing them
KR100196559B1 (ko) 1990-06-19 1999-06-15 기따사또 이찌로 안지오텐신ii 길항작용을 함유하는 피리딘 유도체
NL9001752A (nl) 1990-08-02 1992-03-02 Cedona Pharm Bv Nieuwe 1,4-dihydropyridinederivaten.
IL99731A0 (en) 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
JPH05301872A (ja) 1992-04-23 1993-11-16 Kumiai Chem Ind Co Ltd ピコリン酸誘導体及び除草剤
US5403816A (en) 1990-10-25 1995-04-04 Kumiai Chemical Industry Co., Ltd. Picolinic acid derivative and herbicidal composition
EP0498380A1 (de) 1991-02-08 1992-08-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Komplexbildner
JPH0641118A (ja) 1991-05-31 1994-02-15 Kumiai Chem Ind Co Ltd ピコリン酸誘導体及び除草剤
US5185251A (en) 1991-06-07 1993-02-09 Merck & Co., Inc. Microbial transformation of a substituted pyridinone using actinoplanacete sp. MA 6559
JP2600644B2 (ja) 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5202243A (en) 1991-10-04 1993-04-13 Merck & Co., Inc. Method of hydroxylating 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methyl-2-(1H)-pyridinone by incubation with liver slices
GB9203798D0 (en) 1992-02-21 1992-04-08 Fujisawa Pharmaceutical Co Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
AU4562693A (en) 1992-07-01 1994-01-31 Byk Gulden Lomberg Chemische Fabrik Gmbh Contrast agents for mr diagnosis
US5290941A (en) 1992-10-14 1994-03-01 Merck & Co., Inc. Facile condensation of methylbenzoxazoles with aromatic aldehydes
KR0173145B1 (ko) 1993-04-07 1999-02-01 고바야시 유키오 티아졸리딘 유도체 및 이를 함유하는 약학적 조성물
DE4318550A1 (de) 1993-06-04 1994-12-08 Boehringer Mannheim Gmbh Aryliden-4-oxo-2-thioxo-3- thiazolidincarbonsäuren, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
IL110151A (en) 1993-06-30 1998-10-30 Sankyo Co Amide derivatives and pharmaceutical compositions containing them
JPH0725882A (ja) 1993-07-07 1995-01-27 Res Dev Corp Of Japan アクロメリン酸bおよびeを製造するための中間体と、その製造方法
EP0637586B1 (en) 1993-08-05 1999-06-02 HOECHST MARION ROUSSEL, Inc. 2-(Piperidin-4-yl, pyridin-4-yl and tetrahydropyridin-4-yl)-benzofuran-7-carbamate derivatives, their preparation and their use as acetylcholinesterase inhibitors
EP0640609A1 (en) 1993-08-24 1995-03-01 Ono Pharmaceutical Co., Ltd. Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
AU7992594A (en) 1993-11-19 1995-06-06 Ciba-Geigy Ag Benzothiophene derivatives possessing a methoxyimino substituent as microbicides
EP0658559A1 (de) 1993-12-14 1995-06-21 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren
FI963169A7 (fi) 1994-02-14 1996-08-13 Merrell Pharma Inc Enkefalinaasin ja ACE:n inhibittoreina käyttökelpoisia uusia merkaptoa setyyliamido-1,3,4,5-tetrahydrobents/c/-atsepin-3-onidisulfidijohdanna isia
GB9420557D0 (en) 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
DE4442050A1 (de) 1994-11-25 1996-05-30 Hoechst Ag Heterospiroverbindungen und ihre Verwendung als Elektrolumineszenzmaterialien
US5650408A (en) 1995-06-07 1997-07-22 Karanewsky; Donald S. Thiazolo benzazepine containing dual action inhibitors
TW434240B (en) 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
JP3895404B2 (ja) 1996-05-17 2007-03-22 興和株式会社 カルコン誘導体及びこれを含有する医薬
AU2995497A (en) 1996-07-26 1997-11-19 Dr. Reddy's Research Foundation Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
JP2000516958A (ja) 1996-08-26 2000-12-19 ジェネティックス・インスチチュート・インコーポレーテッド ホスホリパーゼ酵素の阻害剤
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
AU4136197A (en) 1996-09-09 1998-03-26 Kyowa Hakko Kogyo Co. Ltd. Pyrrolocarbazole derivatives
KR20000053201A (ko) 1996-11-12 2000-08-25 한스 루돌프 하우스, 헨리테 브룬너, 베아트리체 귄터 제초제로서 유용한 피라졸 유도체
US6043389A (en) 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US5760232A (en) 1997-06-16 1998-06-02 Schering Corporation Synthesis of intermediates useful in preparing bromo-substituted tricyclic compounds
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6111107A (en) 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
BR9815170A (pt) 1997-12-12 2000-10-10 Euro Celtique S A Luxembourg "método de obter composto aplicável no tratamento de asma em mamìferos"
ID26123A (id) 1998-02-25 2000-11-23 Genetics Inst Penghambat-penghambat phospholipase a2
CA2319493A1 (en) 1998-03-18 1999-09-23 Regine Bohacek Heterocyclic signal transduction inhibitors, compositions containing them
US6214879B1 (en) 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
GB9810860D0 (en) 1998-05-20 1998-07-22 Hoechst Schering Agrevo Gmbh Substituted pyridine and pyrimidines, processes for their preparation and their use as pesticides
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
KR20010052570A (ko) 1998-06-04 2001-06-25 스티븐 에프. 웨인스톡 세포 유착을 억제하는 소염성 화합물
GB9818627D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
US20030060425A1 (en) 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
WO2000035858A1 (en) 1998-12-14 2000-06-22 F. Hoffmann-La Roche Ag Phenylglycine derivatives
US6544980B2 (en) 1998-12-31 2003-04-08 Aventis Pharmaceuticals Inc. N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase
WO2000040564A1 (en) 1998-12-31 2000-07-13 Aventis Pharmaceuticals Inc. N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase
PL350769A1 (en) 1999-03-31 2003-01-27 Basf Ag Substituted aniline compounds
US6251927B1 (en) 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
JP2002544242A (ja) 1999-05-14 2002-12-24 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 酵素活性化抗腫瘍プロドラッグ化合物
US6184228B1 (en) 1999-05-25 2001-02-06 Anadys Pharmaceuticals, Inc. Anti-sickling agents: selection methods and effective compounds
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
ATE258928T1 (de) 1999-06-28 2004-02-15 Janssen Pharmaceutica Nv Respiratorisches syncytialvirus replikation inhibitoren
WO2001023383A1 (en) 1999-09-28 2001-04-05 Eisai Co., Ltd. Quinuclidine compounds and drugs containing the same as the active ingredient
IL149337A0 (en) 1999-11-05 2002-11-10 Emisphere Tech Inc Phenoxy carboxylic acid compounds and compositions for delivering active agents
AUPQ407699A0 (en) 1999-11-16 1999-12-09 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
CZ20022332A3 (cs) 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
WO2001057044A1 (en) 2000-02-01 2001-08-09 Daiichi Pharmaceutical Co., Ltd. Pyridoxazine derivatives
US6506755B2 (en) 2000-02-03 2003-01-14 Hoffmann-La Roche Inc. Thiazolidinecarboxyl acids
AUPQ585000A0 (en) 2000-02-28 2000-03-16 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
JP2003528068A (ja) 2000-03-17 2003-09-24 コリクサ コーポレイション 新規両親媒性アルデヒドならびにアジュバントおよび免疫エフェクターとしてのそれらの使用
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
JP2002022464A (ja) 2000-07-05 2002-01-23 Mazda Motor Corp 移動体用情報処理装置、移動体用情報処理方法、及び移動体用情報処理プログラムが記憶された記憶媒体
HRP20030003B1 (en) 2000-07-14 2011-01-31 F. Hoffmann - La Roche Ag N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
US20020142995A1 (en) 2000-08-01 2002-10-03 Nicolau Yves Claude Ammonium salts of hemoglobin allosteric effectors, and uses thereof
US6653313B2 (en) 2000-08-10 2003-11-25 Warner-Lambert Company Llc 1,4-dihydropyridine compounds as bradykinin antagonists
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
AUPR034000A0 (en) 2000-09-25 2000-10-19 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
KR100846339B1 (ko) 2000-11-20 2008-07-15 바이오비트럼 에이비(피유비엘) 세로토닌 5ht-2 수용체의 아고니스트 또는안타고니스트로서의 피페라지닐피라진 화합물
WO2002051849A1 (en) 2000-12-26 2002-07-04 Daiichi Pharmaceutical Co., Ltd. Cdk4 inhibitors
US7238716B2 (en) 2000-12-28 2007-07-03 Takeda Pharmaceuticals Company Limited Alkanoic acid derivatives process for their production and use thereof
US20030022923A1 (en) 2001-03-01 2003-01-30 Medinox, Inc. Methods for treatment of sickle cell anemia
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
CA2452159A1 (en) 2001-07-23 2003-02-06 Galileo Laboratories, Inc. Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
JP2003075970A (ja) 2001-08-31 2003-03-12 Konica Corp ハロゲン化銀カラー写真感光材料、カラー写真感光材料、その画像形成方法及びデジタル画像情報作製方法
KR100467313B1 (ko) 2001-11-22 2005-01-24 한국전자통신연구원 적색 유기 전기발광 화합물 및 그 제조 방법과 전기발광소자
GB0128499D0 (en) 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003053368A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
US20030190333A1 (en) 2002-02-04 2003-10-09 Corixa Corporation Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
AU2003230985A1 (en) 2002-04-18 2003-11-03 Stephen H. Embury Method and composition for preventing pain in sickle cell patients
US6608076B1 (en) 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
GB0212785D0 (en) 2002-05-31 2002-07-10 Glaxo Group Ltd Compounds
US20060074119A1 (en) 2002-08-08 2006-04-06 Andrews Clarence W Iii Thiophene compounds
EP1548008A4 (en) 2002-08-23 2008-08-06 Kirin Pharma Kk COMPOUND WITH TGF-BETA-HEMMENDER EFFECT AND THIS MEDICAL COMPOSITION CONTAINING
WO2004024705A1 (ja) 2002-09-10 2004-03-25 Takeda Pharmaceutical Company Limited 5員複素環化合物
EP2179987B1 (en) 2002-12-04 2013-02-13 Virginia Commonwealth University Use of heterocyclic carbaldehyde derivatives against sickle cell anemia
US20040181075A1 (en) 2002-12-19 2004-09-16 Weingarten M. David Process of making chalcone derivatives
WO2004058790A1 (ja) 2002-12-25 2004-07-15 Kissei Pharmaceutical Co., Ltd. 含窒素複素環誘導体、それを含有する医薬組成物およびその医薬用途
DE50303264D1 (de) 2003-02-24 2006-06-08 Randolph Riemschneider Kosmetische zusammensetzung mit whitening-effekt, verfahren zu ihrer herstellung und ihre verwendung
US20040186077A1 (en) 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
EP1613613B1 (en) 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
BRPI0411255A (pt) 2003-06-12 2006-08-01 Novo Nordisk As composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
WO2005019220A2 (en) 2003-08-11 2005-03-03 Cellular Genomics Inc. Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
JP4745244B2 (ja) 2003-11-05 2011-08-10 エフ.ホフマン−ラ ロシュ アーゲー Pparアゴニストとしてのフェニル誘導体
AU2004289690A1 (en) 2003-11-10 2005-05-26 Schering Aktiengesellschaft Benzylether amine compounds useful as CCR-5 antagonists
CA2547570A1 (en) 2003-12-02 2005-06-23 Celgene Corporation 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for induction of fetal hemoglobin in individuals having anemia
US7378439B2 (en) 2004-01-20 2008-05-27 Usv, Ltd. Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride
US20070155744A1 (en) 2004-01-30 2007-07-05 Istituto Di Ricerche Di Biologia Molecolare P, Angeletti S.P.A. N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as hiv integrase inhibitors
GB0403038D0 (en) 2004-02-11 2004-03-17 Novartis Ag Organic compounds
JP2007528379A (ja) 2004-03-09 2007-10-11 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Hivインテグラーゼ阻害薬
WO2005086951A2 (en) 2004-03-10 2005-09-22 Threshold Pharmaceuticals, Inc. Hypoxia-activated anti-cancer agents
DE102004015226B3 (de) 2004-03-24 2005-08-25 Siemens Ag Verfahren zum Plasmareinigen eines Werkstücks und zu dessen Durchführung geeignete Vorrichtung
US20070293698A1 (en) 2004-04-22 2007-12-20 Allos Therapeutics, Inc. Compositions of Allosteric Hemoglobin Modifiers and Methods of Making the Same
TW200606133A (en) 2004-06-30 2006-02-16 Sankyo Co Substituted benzene compounds
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US7812037B2 (en) 2004-10-28 2010-10-12 Medicure International, Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
US20080287399A1 (en) 2004-12-14 2008-11-20 Astrazeneca Ab Substituted Aminopyridines and Uses Thereof
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
WO2006088173A1 (ja) 2005-02-21 2006-08-24 Shionogi & Co., Ltd. Hivインテグラーゼ阻害活性を有する2環性カルバモイルピリドン誘導体
WO2006101318A1 (en) 2005-03-19 2006-09-28 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
JP4874958B2 (ja) 2005-03-30 2012-02-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピリジン誘導体を含有する抗真菌剤
GB0506677D0 (en) 2005-04-01 2005-05-11 Btg Int Ltd Iron modulators
SI2465580T1 (sl) 2005-04-28 2014-04-30 Viiv Healthcare Company Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo za HIV integrazo
DE102005025989A1 (de) 2005-06-07 2007-01-11 Bayer Cropscience Ag Carboxamide
JP2006342115A (ja) 2005-06-10 2006-12-21 Shionogi & Co Ltd Hivインテグラーゼ阻害活性を有する多環性化合物
KR20080027908A (ko) 2005-06-30 2008-03-28 프로시디온 리미티드 Gpcr 효능제
CN100562514C (zh) 2005-07-22 2009-11-25 中国科学院上海药物研究所 一类取代丙酰胺衍生物、其制备方法和用途
GB0516270D0 (en) 2005-08-08 2005-09-14 Glaxo Group Ltd Novel compounds
PT1945622E (pt) 2005-10-11 2012-04-09 Univ Pittsburgh Compostos de benzofurano marcados isotopicamente enquanto agentes de imagiologia para proteínas amilóides
AU2006307101A1 (en) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
US20070197532A1 (en) 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
WO2007084914A2 (en) 2006-01-17 2007-07-26 Neurocrine Biosciences, Inc. Phenoxy-substituted pyrimidines as adenosine receptor antagonists
WO2007095495A2 (en) 2006-02-13 2007-08-23 Pharmacopeia, Inc. Benzodiazepine gcnf modulators for stem cell modulation
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
GB0614586D0 (en) 2006-07-22 2006-08-30 Pliva Istrazivacki Inst D O O Pharmaceutical Formulation
CN101113148A (zh) 2006-07-26 2008-01-30 中国海洋大学 二氧哌嗪类化合物及其制备方法和用途
CA2658925C (en) 2006-07-27 2015-07-14 Amorepacific Corporation Novel sulfonylamino acrylamide derivatives, isomer thereof,or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制bcl蛋白質與結合夥伴間之交互作用的化合物及方法
ES2670407T3 (es) 2006-09-03 2018-05-30 Techfields Biochem Co. Ltd Profármacos de acetaminofén solubles en agua cargados positivamente y compuestos relacionados con una tasa de penetración de la piel muy rápida
EP2079739A2 (en) 2006-10-04 2009-07-22 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
WO2008051532A1 (en) 2006-10-23 2008-05-02 Merck & Co., Inc. 2-[1-phenyl-5-hydroxy or methoxy-4alpha-methyl-hexahydroclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands
FR2909379B1 (fr) 2006-11-30 2009-01-16 Servier Lab Nouveaux derives heterocycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2008066145A1 (en) 2006-11-30 2008-06-05 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as vap-1 inhibitor
CN101558038B (zh) 2006-11-30 2013-05-01 国立大学法人东京工业大学 姜黄素衍生物
CA2677949C (en) 2007-02-22 2016-02-09 Paul Anthony Worthington Iminipyridine derivatives and their uses as microbiocides
TWI407960B (zh) 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽b2受體調節劑
EP2149545B1 (en) 2007-05-22 2016-10-05 Sumitomo Chemical Company, Limited Method for producing benzaldehyde compound
WO2009001214A2 (en) 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
RU2440989C2 (ru) 2007-07-17 2012-01-27 Ф.Хоффманн-Ля Рош Аг ИНГИБИТОРЫ 11β-ГИДРОКСИСТЕРОИДНОЙ ДЕГИДРОГЕНАЗЫ
WO2009013335A1 (en) 2007-07-26 2009-01-29 Novartis Ag Organic compounds
TW200918521A (en) 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
CA2703037A1 (en) 2007-10-17 2009-04-23 Novartis Ag Organic compounds
KR20120102117A (ko) 2007-12-04 2012-09-17 에프. 호프만-라 로슈 아게 아이속사졸로-피리딘 유도체
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
JP2009203230A (ja) 2008-01-31 2009-09-10 Daiichi Sankyo Co Ltd ベンジルフェニルグルコピラノシド誘導体を含有する医薬組成物
KR101586104B1 (ko) 2008-02-14 2016-01-15 스미또모 가가꾸 가부시끼가이샤 벤즈알데히드 화합물의 제조 방법
KR20100132073A (ko) 2008-04-11 2010-12-16 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 Pai―1 저해제
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
JP2011136906A (ja) 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
KR101538822B1 (ko) 2008-05-08 2015-07-22 노바 사우쓰이스턴 유니버시티 혈관 내피 성장 인자 수용체에 대한 특이적 억제제
EP2300433A4 (en) 2008-06-04 2012-03-07 Ambrilia Biopharma Inc HIV INTEGRASE INHIBITORS FROM PYRIDOXIN
DE102008027574A1 (de) 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
JP5314330B2 (ja) 2008-06-16 2013-10-16 住友化学株式会社 2−(アリールオキシメチル)ベンズアルデヒドの製造方法およびその中間体
GB0811451D0 (en) 2008-06-20 2008-07-30 Syngenta Participations Ag Novel microbiocides
AR073304A1 (es) 2008-09-22 2010-10-28 Jerini Ag Moduladores del receptor de bradiquinina b2 de molecula pequena
AU2009314299A1 (en) 2008-11-12 2010-05-20 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (FABP)
TW201033201A (en) 2009-02-19 2010-09-16 Hoffmann La Roche Isoxazole-isoxazole and isoxazole-isothiazole derivatives
HUE033494T2 (en) 2009-03-31 2017-12-28 Ligand Pharm Inc Biphenylsulfonamide Endothelin and Angiotensin II Receptor Antagonist for Glomerulosclerosis
US8367654B2 (en) 2009-05-08 2013-02-05 Tetraphase Pharmaceuticals, Inc. 8-AZA tetracycline compounds
US8486965B2 (en) 2009-08-26 2013-07-16 Takeda Pharmaceutical Company Limited Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer
JPWO2011025006A1 (ja) 2009-08-31 2013-01-31 日本ケミファ株式会社 Gpr119作動薬
BR112012005616A2 (pt) 2009-09-21 2016-06-21 Hoffmann La Roche compostos antivirais heterocíclicos
LT4066821T (lt) 2009-11-09 2025-05-12 Wyeth Llc Tabletės pavidalo neratinibo maleato vaistinė forma
TW201139406A (en) 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
KR101698153B1 (ko) 2010-04-26 2017-01-23 광주과학기술원 P2x1 및 p2x3 수용체 길항제로 사용되는 신규한 피리딘 카르복실산계 화합물, 이의 제조방법 및 이를 포함하는 조성물
CN102232949A (zh) 2010-04-27 2011-11-09 孙远 提高药物溶出度的组合物及其制备方法
TWI535442B (zh) 2010-05-10 2016-06-01 Kyowa Hakko Kirin Co Ltd A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine
US20120122928A1 (en) 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
CN102116772B (zh) 2010-09-28 2013-08-28 上海大学 二氢查尔酮化合物的筛选方法
AU2011350396A1 (en) 2010-12-27 2013-07-11 Takeda Pharmaceutical Company Limited Orally disintegrating tablet
US9056838B2 (en) 2011-04-06 2015-06-16 Teva Pharmaceutical Industries Ltd. Intermediates and processes for preparing Ticagrelor
RU2625790C2 (ru) 2011-04-11 2017-07-19 Грин Тек Ко.,Лтд. Новое пиразольное производное
KR20140062472A (ko) 2011-09-15 2014-05-23 데메알엑스, 인크. 노르이보가인 염 무용매화물
US20140308260A1 (en) 2011-10-07 2014-10-16 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
PT3141542T (pt) 2011-12-28 2020-06-16 Global Blood Therapeutics Inc Compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos
EP2797597B1 (en) 2011-12-28 2020-02-26 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
WO2014104384A1 (ja) 2012-12-27 2014-07-03 住友化学株式会社 テトラゾリノン化合物及びその用途
CA2897742A1 (en) 2013-02-19 2014-08-28 Danone, S.A. Functional peptides for obesity disorders
US20140271591A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
AU2014237340C1 (en) 2013-03-15 2018-11-08 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
ES2890077T3 (es) 2013-03-15 2022-01-17 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de la hemoglobina
US20150057251A1 (en) 2013-08-26 2015-02-26 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
ES2710380T3 (es) 2013-03-15 2019-04-24 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de hemoglobina
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
EP2970315B1 (en) 2013-03-15 2021-09-15 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AU2014237330A1 (en) 2013-03-15 2015-09-17 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP2968295A1 (en) * 2013-03-15 2016-01-20 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2015031284A1 (en) * 2013-08-26 2015-03-05 Global Blood Therapeutics, Inc. Formulations comprising wetting agents and compounds for the modulation of hemoglobin (s)
WO2015031285A1 (en) 2013-08-27 2015-03-05 Global Blood Therapeutics, Inc. Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts
US20160207904A1 (en) 2013-08-27 2016-07-21 Global Blood Therapeutics, Inc. Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US20150141465A1 (en) 2013-11-18 2015-05-21 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9248199B2 (en) 2014-01-29 2016-02-02 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
WO2015116061A1 (en) 2014-01-29 2015-08-06 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
PL3102208T5 (pl) 2014-02-07 2024-10-14 Global Blood Therapeutics, Inc. Krystaliczny polimorf wolnej zasady 2-hydroksy-6-((2-(1-izopropylo-1h-pirazol-5-ilo)pirydyn-3-ylo)metoksy)benzaldehydu
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
WO2016043849A2 (en) 2014-07-24 2016-03-24 Global Blood Therapeutics, Inc. Compounds for treating acute respiratory distress syndrome or a negative effect thereof
TWI544395B (zh) 2014-09-26 2016-08-01 義隆電子股份有限公司 單層電容式觸控面板之掃描方法及裝置
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
PL3383392T3 (pl) 2015-12-04 2025-11-17 Global Blood Therapeutics, Inc. Schematy dawkowania dla 2-hydroksy-6-((2-(1-izopropylo-1H-pirazol-5-ilo)pirydyn3-ylo)metoksy)benzaldehydu
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
ES2966707T3 (es) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Moduladores de la hemoglobina para el tratamiento de la drepanocitosis
WO2020106642A1 (en) 2018-11-19 2020-05-28 Global Blood Therapeutics, Inc. 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin

Also Published As

Publication number Publication date
MA43373A (fr) 2018-10-10
SG10201912511WA (en) 2020-02-27
FI3383392T3 (fi) 2025-09-11
US20170157101A1 (en) 2017-06-08
SG11201804647TA (en) 2018-06-28
EP3383392A1 (en) 2018-10-10
PT3383392T (pt) 2025-09-01
WO2017096230A1 (en) 2017-06-08
IL259798A (en) 2018-07-31
US20220378770A1 (en) 2022-12-01
ES3039236T3 (en) 2025-10-20
TW201731509A (zh) 2017-09-16
MX384797B (es) 2025-03-14
DK3383392T3 (da) 2025-08-18
HUE072191T2 (hu) 2025-10-28
BR112018011272A2 (pt) 2018-11-21
US20220110928A1 (en) 2022-04-14
US20210267956A1 (en) 2021-09-02
SI3383392T1 (sl) 2025-10-30
EP3383392B1 (en) 2025-07-09
US11944612B2 (en) 2024-04-02
MX2021008631A (es) 2021-08-19
US11020382B2 (en) 2021-06-01
MX2018006832A (es) 2018-11-09

Similar Documents

Publication Publication Date Title
IL259798A (en) Dosage regimens for 2-hydroxy-6-((2-(1-isopropyl-h1-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
IL285918A (en) Crystal polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
IL265777A (en) Tablets containing 2-hydroxy-6-((2-(1-isopropyl-h1-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
PL3347054T3 (pl) Schematy dawkowania koniugatów przeciwciało anty-TF-lek
ZA201707090B (en) Novel pyridinium compounds
PL3159180T3 (pl) Rolka do przedmiotów ruchomych
GB2540877B (en) A dosing apparatus
FR3025991B1 (fr) Matelas a langer pour bebe
GB201404195D0 (en) Confirmation using multiple CCS measurements
PT3194954T (pt) Dispositivo para caracterização de um objeto em movimento
GB2537080B (en) A dosing device
HK40013372A (en) Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
GB201516634D0 (en) Design method for dosing unit
GB2534627B (en) Accurate mobility chromatograms
IL248688B (en) Method for detecting carcinogenesis in the uterine cervix
FI10822U1 (fi) Paistolaite ruuan valmistusta varten
GB201412223D0 (en) Centralising tape measure